Based on the information provided in the text, here are some key points about Searle Company Limited's proposed transfer and investment:
Transfer of Portfolio: - Searle plans to transfer its portfolio of biological and associated products to Nextar Pharma (Private) Limited. - This includes biologicals, trademarks, authorizations, product registrations, and technical information.
Investment in Nextar: - The company proposes an investment of up to PKR 4 billion (approximately USD 13.8 million at current exchange rates) in Nextar's share capital. - This investment is part of a larger strategy to optimize the group’s product portfolio and improve operational efficiency.
Renaming: - Nextar Pharma will be renamed as Searle Biopharma (Private) Limited. - The proposed name has already been reserved by the Securities and Exchange Commission of Pakistan.
Purpose of Investment: - The investment aims to support the acquisition of the biologics portfolio from Searle Company Limited.
Approval Process: - The board approved these proposals subject to shareholder approvals. - Necessary steps for the transactions will be completed with authorization from relevant officials, including convening an extraordinary general meeting for shareholder approval.
Legal Requirements: - The proposed arrangements are subject to approvals required under Section 199 of the Companies Act, 2017.
This transfer and investment strategy appears to be part of Searle's broader efforts to streamline its operations and align with market demands in the pharmaceutical sector.
